ClinicalTrials.Veeva

Menu

Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy (2009-APBI)

R

Rocky Mountain Cancer Centers

Status and phase

Enrolling
Phase 3

Conditions

Breast Cancer

Treatments

Radiation: accelerated partial breast irradiation - 3D-conformal planning
Radiation: accelerated partial breast irradiation - IMRT planning

Study type

Interventional

Funder types

Other

Identifiers

NCT01185132
2009-APBI
WIRB #20091193 (Other Identifier)

Details and patient eligibility

About

In the setting of radiotherapy as part of breast-conservation therapy for patients with early stage breast cancer, the novel planning and delivery method of intensity modulated radiotherapy is an effective and safe alternative to the commonly-used standard 3D-conformal external beam radiotherapy, spares more normal breast and lung tissue, and may lead to improved clinical outcomes.

Enrollment

660 estimated patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histologically confirmed disease (AJC Classification): Tis, T1, T2 (≤ 3.0 cm), N0, M0.
  • Microscopic multifocal disease is only allowed when the entire span of identified disease measures 3.0 cm or less.
  • Negative surgical margins ( ≥ 0.2 cm) after final surgery.
  • Subjects with infiltrating lobular histologies or high nuclear grade DCIS will be required to have breast MRI scanning as part of the initial staging to verify localized disease.
  • Subjects with DCIS will be included in the study only if they had an MRI prior to lumpectomy.
  • Findings on MRI scanning revealing relevant suspicion of disease outside of planned lumpectomy volume should be further evaluated by ultrasound and, if necessary biopsy, to exclude multicentric/multifocal disease.
  • Subjects with malignant calcifications on mammography will be required to have repeat mammography after surgery to ensure removal of all malignant calcifications.
  • Willing to complete additional screening requirements and meet eligibility criteria as defined in protocol Sec. 4.4.
  • Successful placement of fiducial markers for IGRT requiring nonmigrating fiducials.
  • PTV to ipsilateral breast ratio (IBR) ≤ 25 %.
  • Radiotherapy anticipated to begin within 10 weeks of lumpectomy or re-excision of margins.

Exclusion criteria

  • Pregnancy or breast-feeding.
  • Have collagen-vascular disease.
  • Inadequate surgical margins ( < 0.2 cm) after final surgery.
  • Subjects with persistent malignant/suspicious micro-calcifications.
  • Gross multifocal disease and microscopic disease greater than 3.0 cm.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

660 participants in 2 patient groups

IMRT
Experimental group
Description:
Intensity modulated radiotherapy, 38.5 Gy, 10 fractions over 5 days
Treatment:
Radiation: accelerated partial breast irradiation - IMRT planning
3D-CRT
Active Comparator group
Description:
Three dimensional conformal external radiotherapy, 38.5 Gy, 10 fractions over 5 days
Treatment:
Radiation: accelerated partial breast irradiation - 3D-conformal planning

Trial contacts and locations

5

Loading...

Central trial contact

Rachel Lei, BS; Charles Leonard, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems